{'fraction_non_alphanumeric': 0.029498525073746312, 'fraction_numerical': 0.0009832841691248771, 'mean_word_length': 5.245398773006135, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Research priorities for Parkinson's recommended.

THE EMPHASIS in research on Parkinson's disease should be put on factors that lead to cell death, the study of genetic susceptibility, improvements in drug therapy, and the identification of clinically useful markers. This was the major advice a broad spectrum of neurologic researchers and clinicians handed to the National Institute of Neurological Disorders and Stroke (NINDS) after a 2-day workshop on research priorities related to Parkinson's disease held in Washington, DC. The workshop was convened at the request of Congress. Initially, said Thomas Chase, MD, chief of the experimental therapeutics branch of the NINDS, Congress wanted the institute to hold a consensus meeting to recommend the best ways to treat the disorder. But, he said, there is not yet enough knowledge to reach a consensus. As an alternative, the NINDS, along with two sister National Institutes of Health (NIH) agencies—the National Institute on Aging, Bethesda, Md, and the National